Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device
NCT ID: NCT01552031
Last Updated: 2017-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2011-11-30
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The need of rationalize the utilization of health care resources together with the optimization of patient's care has prompted the development of models of assistance based on home monitoring. At the present time most of the suggested models were based on the utilization of diaries for symptoms perceived by the patients. Even if positive results are reported in terms of reduction of in hospitalization many COPD patients tend to underestimate the severity of their condition and their compliance in recording their symptoms rapidly decreases with time.
Attempts of using more objective measurements such as home spirometers have been done but poor results were reported mainly due to the difficulties in performing a spirometric test without medical supervision.
A more suitable approach to get objective information on the function of the respiratory system is the Forced Oscillation Technique (FOT). Such methodology is based on the analysis of the response of the system to small pressure stimuli over-imposed to the normal breathing of the patients. The measurements require minimal cooperation and can be performed without medical supervision.
The purpose of this study is to measure daily variability of FOT data measured at home of a group of COPD patients in order to identify possible correlations between symptoms change, breathing pattern, lung mechanical impedance and occurrence of exacerbation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02827721
Erythrocytes Membrane Stability in COPD Patients in Long-Term Home Oxygen Therapy
NCT02732444
Domiciliary Monitoring to Predict Exacerbations of COPD
NCT03003702
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
NCT00292552
Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.
NCT05922202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Among these pathologies chronic obstructive pulmonary disease (COPD) is the more important for number of patients and deaths affecting 80 million people in the world \[WHO, 2006\]. The time course of the disease is characterized by stable periods broken up by intermittent acute exacerbations of the symptoms, during which a severe inflammatory process occurs, leading to increased airways obstruction. During exacerbations the risk of death is very high \[Connors et al, 1996;Soler-Cataluna et al, 2005\]. Moreover the frequency and severity of exacerbations correlate with the worsening of the health condition of the patient \[Anzueto et al, 2009; Donaldson et al, 2002\].
The burden of care of patients with COPD on the national health care systems and society is high. The utilization of health care resources by patients with COPD is primarily due to acute exacerbations requiring care in the emergency rooms and hospital \[Dal Negro, 2008\] .
In the last few years the need to rationalize the health care costs has prompted to the development of new technologies for the home monitoring of these patients mainly aimed at the early detection of the onset of exacerbations. This could help the development of new therapeutic and organizational models aimed at reducing the impact of such events on the quality of life of the patient and on the national health care systems.
Published data offer several different follow-up models of home monitoring of COPD. Written and electronic diaries, questionnaires, telephonic assistance by respiratory nurses or specialized clinical personnel and use of web-based call centers have all been suggested for the follow up of patients after discharge from hospitals. Even if positive results are reported in terms of reduction of in hospitalization \[Vitacca et al, 2009\] many COPD patients tend to underestimate the severity of their condition \[Cote et al, 1998\] and patient's compliance in recording their symptoms rapidly decreases with time \[Cote et al, 1998\]. Moreover, other authors address the difficulty to evaluate correctly the impact of such models on patient's quality of life and on the reduction of hospitalization and mortality rate \[Ram et al, 2004; Bolton et al, 2010\].
An effective home monitoring system for COPD patients should have the following characteristics:
1. easy to be used in unsupervised environment,
2. able to provide sensible and objective information about patient status,
3. low cost.
Clinically, diagnosis and monitoring of COPD patients is based on spirometric parameters, such as FEV1 (forced expiratory volume in 1 second), FVC (forced vital capacity) and FEV1/FVC obtained from forced expiratory maneuvers \[Gold, 2009\]. However, for most patients affected by COPD, it is very difficult to execute spirometry correctly because of their poor ability to perform forced maneuvers. For this reason it is necessary that the test is supervised by a physician \[Miller et al, 2005\]. Moreover, there is general belief in the medical community that FEV1 is insensitive to changes over short periods of time in patients with COPD so controversy surrounds the reliance of this parameter as an accurate metric for acute respiratory events.
These may be some of the reasons why most of the studies where patients have been monitored by home spirometry or peak-flow meters have reported poor results\[Brouwer et al, 2010\].
A promising technology for the home monitoring of respiratory diseases is represented by the Forced Oscillations Technique (FOT). FOT is based on the analysis of the response of the respiratory system to external pressure stimuli superimposed to the spontaneous breathing of the patient. It does not require the cooperation of the patient and it can provide accurate measurements even without the supervision of specialized personnel.
In the last few years new technologies based on FOT and special algorithms were developed by the respiratory research group of the Bioengineering Department of the Politecnico di Milano University, Italy. These methodologies have been already tested proving to be effective for the automatic and quantitative evaluation of several phenomena including:
* the presence or not of Expiratory Flow Limitation (EFL) breath by breath \[Dellaca' et al, 2004\];
* airways resistance corrected from the artifacts introduced by EFL \[Dellaca' et al, 2009\];
* the degree of airways heterogeneities measured by the analysis of the frequency dependency of the resistance;
* the response of the respiratory system to the administration of bronchodilators and bronchoconstrictors \[Dellaca' et al, 2009\].
Recently a spin-off company of respiratory group of the Bioengineering Department of the Politecnico di Milano has made available a special device (RESMONPRO-diary) suitable to collect data at patient's home without medical supervision. Data from a prototype device recorded on asthmatic patients have shown its suitability for remote unsupervised monitoring of chronic conditions.
AIM OF THE STUDY
The aim of the present study is to evaluate the possibility of monitoring oscillatory parameters of lung mechanics, measured by the Forced Oscillation Technique (FOT), for the early detection of exacerbations in COPD patients.
Therefore primary outcome will be the identification of the relationship between changes in patient's symptoms, breathing pattern, lung mechanical impedance indices and occurrence of and exacerbation.
A further outcome of the study will be the identification and classification of the occurred exacerbations.
STUDY PROTOCOL
Pre-study measurements:
After the enrollment in the study, every subject will be visited by physician and will undergo a standard pulmonary function test.
Moreover the following data will be collected:
* exacerbation history
* smoking history
* disease history
* presence of co-morbidities
Daily home monitoring program:
All patients will be monitored at home using a device for oscillometric measurement of lung functionality (RESMON pro).
The duration of the measurement will be 2-3 minutes once a day for a period comprised between 6 and 8 months. At the beginning of the measurement the device will ask the patient to fill a simple questionnaire for self-evaluation of their symptoms (dyspnoea, amount and purulence of sputum, wheeze, cough). For the duration of the study, the participant will be asked to wear an Actiwatch Spectrum 24 hours a day. The Actiwatch Spectrum, a small watch-like device, measures activity by recording and analyzing the readings from the on-board accelerometer. Each 1-minute activity epoch is analyzed and the statistical results stored in the on-board memory which can hold up to six-months of data. The Actigraphy data provides an objective record of activity and has been validated to determine normal and abnormal sleep / wake patterns.
A nurse will perform a weekly phone interview in order to collect information about presence and timing of the following events:
* Change in current drug therapy
* Systemic steroids use/prescription
* Antibiotic use/prescription
* Hospitalization due to respiratory causes
* Emergency Room admission
* Unscheduled GP call
* Unscheduled GP visit
* Specialist visit
* Worsening in sleep
* Worsening in dyspnea during daily life activity
* Fever
DATA ANALYSIS
The time-series data and their variability will be analyzed using the method of the time irreversibility, sample and multiscale entropy, and Gumbel's extreme values statistic. The predictor of an exacerbation will then be derived by calculating the conditional probability of having a future acute event given the trend or the variability of indices derived from the above methods. Additionally data will be analyzed also using a deterministic approach: linear and non-linear modelling analysis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who reported more than two exacerbations in the past year OR
* patients who required more than two hospital admission in the last year OR
* patients with ER admission in the last year due to acute respiratory failure
better if:
* depressive phenotype
* worsening of dyspnea during walk (measured by MRC-Medical Research Council score)
* malnutrition or obesity (BMI \< 19 or \> 25)
* patient lives alone
Exclusion Criteria
* Alpha-1antitrypsin deficiency
* Significant inflammatory diseases other than COPD
* Organ or systemic diseases that may impair the ventilatory function (any restrictive pulmonary disease, cystic fibrosis and so on)
* Prior lung surgery
* Concomitant enrollment in other trials
* Any major non-COPD disease or condition, such as uncontrolled malignancy, end-stage heart disease, liver or renal insufficiency (that requires current evaluation for liver or renal transplantation or dialysis), amyotrophic lateral sclerosis, or severe stroke, or other as deemed appropriate by investigator as determined by review of medical history and / or patient reported medical history
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Restech Srl
INDUSTRY
Politecnico di Milano
OTHER
Fondazione Salvatore Maugeri
OTHER
Azienda Ospedaliera S. Luigi, Orbassano (TO)
UNKNOWN
Baylor College of Medicine
OTHER
Ospedale di Circolo e Fondazione Macchi, Varese
UNKNOWN
Woolcock Institute of Medical Research
OTHER
Raffaele Dellaca
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raffaele Dellaca
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raffaele L Dellaca', PhD
Role: PRINCIPAL_INVESTIGATOR
Politecnico di Milano, Italy
Michele Vitacca, MD
Role: PRINCIPAL_INVESTIGATOR
Pneumology Division Fondazione Salvatore Maugeri, IRCCS, Lumezzane, Italy
Alessandro Gobbi, PhD
Role: PRINCIPAL_INVESTIGATOR
Politecnico di Milano, Italy
Pasquale P Pompilio, PhD
Role: PRINCIPAL_INVESTIGATOR
Politecnico di Milano, Italy
Emanuela Zannin, PhD
Role: PRINCIPAL_INVESTIGATOR
Politecnico di Milano, Italy
Carlo Gulotta, MD
Role: PRINCIPAL_INVESTIGATOR
Pneumologia-Fisiopatologia Respiratoria, Azienda Ospedaliera S. Luigi Gonzaga Orbassano, Torino, Italy
Amir Sharafkhaneh, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Sleep Disorders & Research Center Michael E. DeBakey VA Medical Center
Piero Ceriana, MD
Role: PRINCIPAL_INVESTIGATOR
Unità Operativa di Riabilitazione Pneumologica, Fondazione Salvatore Maugeri, IRCCS, Pavia, Italy
Fausto Colombo, MD
Role: PRINCIPAL_INVESTIGATOR
Direttore U.O. Pneumologia - A.O. Ospedale di Circo lo e Fondazione Macchi, Varese
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Woolcock Institute of Medical Research
Glebe, New South Wales, Australia
Divisione di Pneumologia, Fondazione S. Maugeri, IRCCS
Lumezzane, BS, Italy
Pneumologia-Fisiopatologia Respiratoria, Azienda Ospedaliera S. Luigi Gonzaga
Orbassano, Torino, Italy
Unità Operativa di Riabilitazione Pneumologica, Fondazione S. Maugeri, IRCCS
Pavia, , Italy
U.O. Pneumologia - A.O. Ospedale di Circolo e Fondazione Macchi
Varese, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
United Nations Population Division, World Population Ageing: 1950-2050 2002.
Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):959-67. doi: 10.1164/ajrccm.154.4.8887592.
Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005 Nov;60(11):925-31. doi: 10.1136/thx.2005.040527. Epub 2005 Jul 29.
Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis. 2009;4:245-51. doi: 10.2147/copd.s4862. Epub 2009 Jul 20.
Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847-52. doi: 10.1136/thorax.57.10.847.
Dal Negro R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(1):1-10. doi: 10.2147/copd.s671.
Vitacca M, Bianchi L, Guerra A, Fracchia C, Spanevello A, Balbi B, Scalvini S. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J. 2009 Feb;33(2):411-8. doi: 10.1183/09031936.00005608. Epub 2008 Sep 17.
Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002 Oct;20(4):799-805. doi: 10.1183/09031936.02.03242002.
Cote J, Cartier A, Malo JL, Rouleau M, Boulet LP. Compliance with peak expiratory flow monitoring in home management of asthma. Chest. 1998 Apr;113(4):968-72. doi: 10.1378/chest.113.4.968.
Ram FS, Wedzicha JA, Wright J, Greenstone M. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ. 2004 Aug 7;329(7461):315. doi: 10.1136/bmj.38159.650347.55. Epub 2004 Jul 8.
Bolton CE, Waters CS, Peirce S, Elwyn G; EPSRC and MRC Grand Challenge Team. Insufficient evidence of benefit: a systematic review of home telemonitoring for COPD. J Eval Clin Pract. 2011 Dec;17(6):1216-22. doi: 10.1111/j.1365-2753.2010.01536.x. Epub 2010 Sep 16.
Gold PM. The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care. 2009 Aug;54(8):1040-9.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.
Brouwer AF, Visser CA, Duiverman EJ, Roorda RJ, Brand PL. Is home spirometry useful in diagnosing asthma in children with nonspecific respiratory symptoms? Pediatr Pulmonol. 2010 Apr;45(4):326-32. doi: 10.1002/ppul.21183.
Dellaca RL, Santus P, Aliverti A, Stevenson N, Centanni S, Macklem PT, Pedotti A, Calverley PM. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J. 2004 Feb;23(2):232-40. doi: 10.1183/09031936.04.00046804.
Dellaca RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J. 2009 Jun;33(6):1329-37. doi: 10.1183/09031936.00139608. Epub 2009 Jan 22.
Zimmermann SC, Huvanandana J, Nguyen CD, Bertolin A, Watts JC, Gobbi A, Farah CS, Peters MJ, Dellaca RL, King GG, Thamrin C. Day-to-day variability of forced oscillatory mechanics for early detection of acute exacerbations in COPD. Eur Respir J. 2020 Sep 10;56(3):1901739. doi: 10.1183/13993003.01739-2019. Print 2020 Sep.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COPD-FOT-MON1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.